FLNA
Filana Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.82
−0.99%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 910.0K | 936.0K | — | — | — |
| Gross Profit | (910.0K) | (936.0K) | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 15.7M | 26.6M | 69.6M | 89.4M | 68.0M |
| SG&A Expense | 29.4M | 67.9M | 71.8M | 16.5M | 12.0M |
| General & Admin Expense | 7.9M | — | 71.8M | 16.5M | 12.0M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 45.1M | 94.5M | 141.4M | 106.0M | 80.0M |
| Cost and Expenses | 46.0M | 95.4M | 141.4M | 106.0M | 80.0M |
| Operating Income (EBIT) | (46.0M) | (95.4M) | (141.4M) | (106.0M) | (80.0M) |
| Non-Operating | |||||
| Interest Income | 3.7M | 4.6M | 8.5M | 7.8M | 2.8M |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 3.7M | 4.6M | 8.5M | 7.8M | 2.8M |
| Other Non-Op Income/Expense | 3.7M | 4.4M | 117.1M | 8.7M | 3.8M |
| Non-Operating Income (excl Interest) | (2.9M) | (4.4M) | 832.0K | 1.4M | 1.5M |
| EBT (Pre-Tax Income) | (42.3M) | (91.0M) | (24.3M) | (97.2M) | (76.2M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (42.3M) | (91.0M) | (24.3M) | (97.2M) | (76.2M) |
| Earnings from Cont. Ops | (42.3M) | (91.0M) | (24.3M) | (97.2M) | (76.2M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (42.3M) | (91.0M) | (68.1M) | (97.2M) | (76.2M) |
| Per Share | |||||
| Basic EPS | ($0.87) | ($1.88) | ($0.53) | ($2.32) | ($1.90) |
| Diluted EPS | ($0.87) | ($1.88) | ($1.46) | ($2.32) | ($1.90) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 48.3M | 48.3M | 46.3M | 41.9M | 40.2M |
| Diluted Shares Outstanding | 48.3M | 48.3M | 4.7B | 41.9M | 40.2M |
| Profitability Metrics | |||||
| EBITDA | (42.0M) | (90.0M) | (141.1M) | (105.8M) | (80.2M) |
| D&A | 1.0M | 936.0K | 1.1M | 1.5M | 1.3M |
| EBIT | (43.1M) | (91.0M) | (142.3M) | (107.3M) | (81.5M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026